About
Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Braveheart Bio, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:BRVE
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Analyst Estimates
Street consensus and price targets
Risk Metrics
Volatility versus the market
Earnings Calendar
Upcoming and recent earnings
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | $27.50 | $29.00 | $27.50 | $27.86 | $27.86 | +0.36 | 127,800 |
| 2026-08-26 | $27.80 | $28.65 | $27.01 | $27.76 | $27.76 | -0.04 | 215,200 |
| 2026-08-25 | $28.29 | $29.25 | $27.07 | $27.64 | $27.64 | -0.65 | 155,300 |
| 2026-08-24 | $27.64 | $28.00 | $26.17 | $27.50 | $27.50 | -0.14 | 102,000 |
| 2026-08-21 | $27.49 | $28.10 | $27.12 | $27.58 | $27.58 | +0.09 | 130,500 |
| 2026-08-20 | $28.43 | $28.89 | $26.54 | $27.42 | $27.42 | -1.01 | 176,200 |
| 2026-08-19 | $26.99 | $30.12 | $26.86 | $28.97 | $28.97 | +1.98 | 391,800 |
| 2026-08-18 | $27.64 | $28.50 | $25.76 | $26.75 | $26.75 | -0.89 | 215,000 |
| 2026-08-17 | $26.97 | $28.29 | $26.67 | $27.66 | $27.66 | +0.69 | 310,200 |
| 2026-08-14 | $25.92 | $27.15 | $25.01 | $27.03 | $27.03 | +1.11 | 330,000 |
| 2026-08-13 | $26.10 | $26.64 | $24.88 | $25.97 | $25.97 | -0.13 | 707,600 |
| 2026-08-12 | $24.90 | $26.67 | $24.90 | $26.15 | $26.15 | +1.25 | 634,000 |
| 2026-08-11 | $27.53 | $27.88 | $24.61 | $25.01 | $25.01 | -2.52 | 724,700 |
| 2026-08-10 | $30.78 | $32.00 | $27.45 | $27.53 | $27.53 | -3.25 | 415,700 |
| 2026-08-07 | $29.70 | $32.00 | $28.47 | $30.00 | $30.00 | +0.30 | 566,600 |
| 2026-08-06 | $30.20 | $31.56 | $29.42 | $29.80 | $29.80 | -0.40 | 3,292,200 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Aug 18, 2026 | Filing |
| SCHEDULE 13D | Aug 14, 2026 | Filing |
| SCHEDULE 13G | Aug 14, 2026 | Filing |
| 8-K | Aug 7, 2026 | Current Report |
| S-8 | Aug 6, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Aug 6, 2026 | Prospectus |
| CERT | Aug 6, 2026 | Certification by an exchange approving securities for listing |
| EFFECT | Aug 5, 2026 | Notice of Effectiveness |
| S-1MEF | Aug 5, 2026 | Registration adding securities to prior Form S-1 registration |
| 8-A12B | Aug 3, 2026 | Registration of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Travis Murdoch, M.D.
Chief Executive Officer, President and Director
Michele Anderson
Chief Development Officer
J. Paul Rickey
Chief Financial Officer
Tyler Chavez
Chief Business Officer
Marc Evanchik, M.S.
Chief Scientific Officer
Emil deGoma
Chief Medical Officer
Christopher Viehbacher
Chairman of the Board
Vineeta Agarwala, M.D., Ph.D.
Director
Jasper Bos, Ph.D.
Director
Erez Chimovits, M.B.A., M.Sc.
Director
